Takeda applies for additional indications for lansoprazole

Takeda revealed this week that it has submitted an application for further indications regarding its Takepron Capsules 15 and Takepron OD Tablet 15 (lansoprazole).

Lansoprazole is a proton pump inhibitor which has already been approved for the treatment of gastric ulcers, duodenal ulcers and reflux esophagitis in patients treated with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Now the firm is hoping to receive confirmation that the therapy can be used in those undergoing long-term treatment with NSAIDs to prevent the onset of gastric ulcers.

NSAIDS, while intended to curb pain, fever and inflammation, can also bring about the onset of gastric ulcers in patients that are prescribed them.

Takeda is aiming to tackle this issue by introducing lansoprazole as an option to those being treated with NSAIDs for rheumatoid arthritis and osteoarthritis.

In other company news this month, the firm establish the Takeda Wellbeing Programme 2009 – which is entitled Giving Children in Long-term Treatment the Energy to Live.